预测慢性丙型肝炎索非布韦 8 周治疗反应的 IFNL4 基因型和其他个人特征

IF 14.3 1区 医学 Q1 INFECTIOUS DISEASES
{"title":"预测慢性丙型肝炎索非布韦 8 周治疗反应的 IFNL4 基因型和其他个人特征","authors":"","doi":"10.1016/j.jinf.2024.106258","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Shorter duration therapy for hepatitis C virus (HCV) infection might reduce treatment costs and increase the number of patients treated and cured. We determined factors associated with treatment response after an 8-week sofosbuvir-based therapy and developed a simple model to predict an individual’s likelihood of treatment success.</p></div><div><h3>Methods</h3><p>Among 2907 patients who received ledipasvir/sofosbuvir for 8 weeks, we determined failure rates by demographic and clinical characteristics, and <em>IFNL4</em>-∆G/TT genotype. We estimated the average <em>IFNL4</em> genotype-related treatment failure rate in major ancestry groups by applying our <em>IFNL4</em> genotype results to genotype distributions from reference populations. We created a treatment response model based on three personal characteristics.</p></div><div><h3>Results</h3><p>Overall, 4.4% of the patients failed treatment. We observed significantly lower failure rates for persons &lt;50 years (1.6%), females (2.6%), those carrying the <em>IFNL4</em>-TT/TT genotype (1.8%), those with HCV RNA &lt;5.8 log<sub>10</sub> copies/mL (2.0%) or HCV genotype-1B infection (2.6%). In a model based on ancestry, age and sex, the predicted probability of treatment failure ranged from 0.5% among females of East Asian ancestry &lt;50 years of age to 8.5% among males of African ancestry age ≥65 years.</p></div><div><h3>Conclusion</h3><p>Applying this algorithm at the point-of-care might facilitate HCV elimination, especially in low- and middle-income countries.</p></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":null,"pages":null},"PeriodicalIF":14.3000,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324001920/pdfft?md5=03e998d5cd0e3ffa3661cca7eb8805e6&pid=1-s2.0-S0163445324001920-main.pdf","citationCount":"0","resultStr":"{\"title\":\"IFNL4 genotype and other personal characteristics to predict response to 8-week sofosbuvir-based treatment for chronic hepatitis C\",\"authors\":\"\",\"doi\":\"10.1016/j.jinf.2024.106258\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Shorter duration therapy for hepatitis C virus (HCV) infection might reduce treatment costs and increase the number of patients treated and cured. We determined factors associated with treatment response after an 8-week sofosbuvir-based therapy and developed a simple model to predict an individual’s likelihood of treatment success.</p></div><div><h3>Methods</h3><p>Among 2907 patients who received ledipasvir/sofosbuvir for 8 weeks, we determined failure rates by demographic and clinical characteristics, and <em>IFNL4</em>-∆G/TT genotype. We estimated the average <em>IFNL4</em> genotype-related treatment failure rate in major ancestry groups by applying our <em>IFNL4</em> genotype results to genotype distributions from reference populations. We created a treatment response model based on three personal characteristics.</p></div><div><h3>Results</h3><p>Overall, 4.4% of the patients failed treatment. We observed significantly lower failure rates for persons &lt;50 years (1.6%), females (2.6%), those carrying the <em>IFNL4</em>-TT/TT genotype (1.8%), those with HCV RNA &lt;5.8 log<sub>10</sub> copies/mL (2.0%) or HCV genotype-1B infection (2.6%). In a model based on ancestry, age and sex, the predicted probability of treatment failure ranged from 0.5% among females of East Asian ancestry &lt;50 years of age to 8.5% among males of African ancestry age ≥65 years.</p></div><div><h3>Conclusion</h3><p>Applying this algorithm at the point-of-care might facilitate HCV elimination, especially in low- and middle-income countries.</p></div>\",\"PeriodicalId\":50180,\"journal\":{\"name\":\"Journal of Infection\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":14.3000,\"publicationDate\":\"2024-08-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0163445324001920/pdfft?md5=03e998d5cd0e3ffa3661cca7eb8805e6&pid=1-s2.0-S0163445324001920-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Infection\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0163445324001920\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infection","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0163445324001920","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

背景:缩短丙型肝炎病毒(HCV)感染的治疗时间可降低治疗成本,增加治疗和治愈患者的数量。我们确定了基于索非布韦的 8 周治疗后治疗反应的相关因素,并建立了一个简单的模型来预测个人治疗成功的可能性:在 2907 名接受了 ledipasvir/sofosbuvir 8 周治疗的患者中,我们根据人口统计学特征、临床特征和 IFNL4-∆G/TT 基因型确定了失败率。我们将 IFNL4 基因型结果应用于参考人群的基因型分布,从而估算出主要血统群体中与 IFNL4 基因型相关的平均治疗失败率。我们根据三个个人特征创建了一个治疗反应模型:结果:总体而言,4.4% 的患者治疗失败。我们观察到,10拷贝数/毫升(2.0%)或HCV基因型-1B感染者(2.6%)的治疗失败率明显较低。在基于血统、年龄和性别的模型中,东亚血统 65 岁女性的预测治疗失败概率为 0.5%:结论:在医疗点应用该算法可能有助于消灭 HCV,尤其是在中低收入国家。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

IFNL4 genotype and other personal characteristics to predict response to 8-week sofosbuvir-based treatment for chronic hepatitis C

IFNL4 genotype and other personal characteristics to predict response to 8-week sofosbuvir-based treatment for chronic hepatitis C

Background

Shorter duration therapy for hepatitis C virus (HCV) infection might reduce treatment costs and increase the number of patients treated and cured. We determined factors associated with treatment response after an 8-week sofosbuvir-based therapy and developed a simple model to predict an individual’s likelihood of treatment success.

Methods

Among 2907 patients who received ledipasvir/sofosbuvir for 8 weeks, we determined failure rates by demographic and clinical characteristics, and IFNL4-∆G/TT genotype. We estimated the average IFNL4 genotype-related treatment failure rate in major ancestry groups by applying our IFNL4 genotype results to genotype distributions from reference populations. We created a treatment response model based on three personal characteristics.

Results

Overall, 4.4% of the patients failed treatment. We observed significantly lower failure rates for persons <50 years (1.6%), females (2.6%), those carrying the IFNL4-TT/TT genotype (1.8%), those with HCV RNA <5.8 log10 copies/mL (2.0%) or HCV genotype-1B infection (2.6%). In a model based on ancestry, age and sex, the predicted probability of treatment failure ranged from 0.5% among females of East Asian ancestry <50 years of age to 8.5% among males of African ancestry age ≥65 years.

Conclusion

Applying this algorithm at the point-of-care might facilitate HCV elimination, especially in low- and middle-income countries.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Infection
Journal of Infection 医学-传染病学
CiteScore
45.90
自引率
3.20%
发文量
475
审稿时长
16 days
期刊介绍: The Journal of Infection publishes original papers on all aspects of infection - clinical, microbiological and epidemiological. The Journal seeks to bring together knowledge from all specialties involved in infection research and clinical practice, and present the best work in the ever-changing field of infection. Each issue brings you Editorials that describe current or controversial topics of interest, high quality Reviews to keep you in touch with the latest developments in specific fields of interest, an Epidemiology section reporting studies in the hospital and the general community, and a lively correspondence section.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信